The picture below illustrates the quantities of food that would need to be consumed daily, on top of a normal diet, to obtain the levels of nutrients that one 125ml bottle of Souvenaid® provides. Click on the components on the left hand side of the picture to view a breakdown of the dietary equivalence of each component in Souvenaid®.
Select component to see the amount in Souvenaid® and dietary equivalent
Amount in Souvenaid® (125 ml)
1200mg/300mg
Dietary Equivalent
4 tins of tuna/100g fresh tuna
Amount in Souvenaid® (125 ml)
625 mg
Dietary Equivalent
1 kg tomatoes
Amount in Souvenaid® (125 ml)
400 mg
Dietary Equivalent
100g minced beef
Amount in Souvenaid® (125 ml)
106 mg
Dietary Equivalent
4 eggs
Amount in Souvenaid® (125 ml)
Folic Acid:
400 μg
Vitamin B6:
1 mg
Vitamin B12:
3 μg
Vitamin C:
80 mg
Vitamin E:
40 mg
Selenium:
60 μg
Dietary Equivalent
Folic Acid:
1.2kg broccolli
Vitamin B6:
710g spinach
Vitamin B12:
Contained in tuna
Vitamin C:
1 orange
Vitamin E:
Contained in tuna portion
Selenium:
Handful of brazil nuts
DHA and EPA are Omega-3 Fatty Acids
DHA = Docosahexaenoic acid; EPA = Eicosapentaenoic acid
UMP = Uridine Monophosphate
1. Jonas, DA et al. Ann Nutrition Metabol 2001;45:235-254.
2. Oruna-Concha, MJ et al. J Agric Food Chem 2007;55:5776-5780.
3. Data from Canadian Nutrient File, 2007 (www.hc-sc.gc.ca).
4. Data from:Food Composition and Nutrition Tables (5 ed), Medpharm Scientific Publ. (Stuttgart), 1994.
5. Data from: USDA Database for the Choline Content of Common Foods (www.ars.usda.gov).
Research has shown that people with memory loss in early Alzheimer’s disease often have low levels of the above key nutrients.
For people with early Alzheimer’s disease, who are subject to an accelerated loss of brain connections, it’s important to consistently maintain the right levels and combination of these key nutrients.
References:
1. Lopes da Silva S, et al. Alzheimer’s & Dementia 2014; 10(4); 485-502.
2. Mi W, et al. Nutrition 29: 1080-1089.
Two clinical trials have been carried out to look at the effect of Souvenaid® on patients with mild Alzheimer’s disease. Souvenir I trial, investigated the effects of Souvenaid® over a 12 week period1while in Souvenir II the study period was extended to a 24 week period2
All trials showed, in patients taking Souvenaid®, the nutrients were absorbed, as reflected in the increased measured blood samples during the trial period, resulting in improved nutritional status1-2.
References:
1. Scheltens P, et al. Alzheimers Dement. 2010 Jan;6(1)1-10.e1.
2. Scheltens P, et al. J Alzheimer’s Dis. 2012;31: 225-236.1.
IMPORTANT. PLEASE READ.
This website contains information about Alzheimer’s disease and Souvenaid®, a product used in the dietary management of the early stages of Alzheimer’s disease. You must seek advice from your doctor, nurse or pharmacist if you are unsure of your condition or diagnosis or if you would like to use Souvenaid®. The information, opinions and recommendations presented on this website are not intended to replace the care of your doctor, nurse or pharmacist. Please see full Terms and Conditions on website